Identification of modulating residues defining the catalytic cleft of insulin-regulated aminopeptidase

Ye, Siying, Chai, Siew Yeen, Lew, Rebecca A., Ascher, David B., Morton, Craig J., Parker, Michael W. and Albiston, Anthony L. 2008, Identification of modulating residues defining the catalytic cleft of insulin-regulated aminopeptidase, Biochemistry and cell biology, vol. 86, no. 3, pp. 251-261, doi: 10.1139/O08-037.

Attached Files
Name Description MIMEType Size Downloads

Title Identification of modulating residues defining the catalytic cleft of insulin-regulated aminopeptidase
Author(s) Ye, SiyingORCID iD for Ye, Siying orcid.org/0000-0002-0882-1642
Chai, Siew Yeen
Lew, Rebecca A.
Ascher, David B.
Morton, Craig J.
Parker, Michael W.
Albiston, Anthony L.
Journal name Biochemistry and cell biology
Volume number 86
Issue number 3
Start page 251
End page 261
Total pages 11
Publisher NRC Research Press
Place of publication Ottawa, Canada
Publication date 2008-06-01
ISSN 0829-8211
1208-6002
Keyword(s) angiotensin IV
IRAP
aminopeptidase
enzyme inhibitors
Summary Inhibition of insulin-regulated aminopeptidase (IRAP) has been demonstrated to facilitate memory in rodents, making IRAP a potential target for the development of cognitive enhancing therapies. In this study, we generated a 3-D model of the catalytic domain of IRAP based on the crystal structure of leukotriene A4 hydrolase (LTA4H). This model identified two key residues at the ‘entrance’ of the catalytic cleft of IRAP, Ala427 and Leu483, which present a more open arrangement of the S1 subsite compared with LTA4H. These residues may define the size and 3-D structure of the catalytic pocket, thereby conferring substrate and inhibitor specificity. Alteration of the S1 subsite by the mutation A427Y in IRAP markedly increased the rate of substrate cleavage V of the enzyme for a synthetic substrate, although a corresponding increase in the rate of cleavage of peptide substrates Leu-enkephalin and vasopressin was was not apparent. In contrast, [L483F]IRAP demonstrated a 30-fold decrease in activity due to changes in both substrate affinity and rate of substrate cleavage. [L483F]IRAP, although capable of efficiently cleaving the N-terminal cysteine from vasopressin, was unable to cleave the tyrosine residue from either Leu-enkephalin or Cyt6-desCys1-vasopressin (2–9), both substrates of IRAP. An 11-fold reduction in the affinity of the peptide inhibitor norleucine1-angiotensin IV was observed, whereas the affinity of angiotensin IV remained unaltered. In additionm we predict that the peptide inhibitors bind to the catalytic site, with the NH2-terminal P1 residue occupying the catalytic cleft (S1 subsite) in a manner similar to that proposed for peptide substrates.
Language eng
DOI 10.1139/O08-037
Field of Research 119999 Medical and Health Sciences not elsewhere classified
Socio Economic Objective 970111 Expanding Knowledge in the Medical and Health Sciences
HERDC Research category C1.1 Refereed article in a scholarly journal
Copyright notice ©2008, NRC Canada
Persistent URL http://hdl.handle.net/10536/DRO/DU:30040957

Document type: Journal Article
Collection: School of Medicine
Connect to link resolver
 
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 17 times in TR Web of Science
Scopus Citation Count Cited 17 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 298 Abstract Views, 4 File Downloads  -  Detailed Statistics
Created: Wed, 07 Dec 2011, 10:05:36 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.